About Samrat Pharmachem Limited
Data last updated:
Samrat Pharmachem Limited is a public limited company based in Ankleshwar, Gujarat, India. It operates in the specialty chemicals segment of the chemicals and materials sector. It was incorporated on 16 June 1992 and has been in existence for over 34 years.
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L24230GJ1992PLC017820. Its GSTIN is 24AAECS0806M2ZE (Gujarat). The company holds 3 GST registrations, of which 1 is active. It is a listed company as per MCA records. Its shares are listed on BSE: 530125.
The company has an authorised share capital of ₹5 Cr and a paid-up capital of ₹3.09 Cr. It is led by directors including Lalit Damodar Mehta (Managing Director) and Megh Rajesh Mehta (Whole-Time Director).
Its last annual general meeting (AGM) was held on 25 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Ankleshwar, Gujarat.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹289.72 Cr, a growth of 1.4% compared to the previous year. For the same year it recorded a net loss of ₹3.65 Cr (net margin -1.3%) and EBITDA of -₹2.15 Cr (EBITDA margin -0.7%). The net worth stands at ₹68.18 Cr (down 5% YoY). Total assets are valued at ₹78.89 Cr (down 3.5% YoY).
The company has about 26 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Samrat Pharmachem. As per MCA filings, the company has open charges of ₹69 Cr and satisfied charges of ₹17.55 Cr on record. Court records list 20 cases involving the company, including 7 filed by the company and 13 filed against it; 1 case is pending. The company has 31 deals on record (31 market trades); the latest was in September 2024. Its 4 peer companies in the Chemicals industry (Specialty Chemicals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 3 larger and 1 smaller; the largest is Toyotsu Rare Earths India Private Limited with revenue of ₹307.7 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website samratpharmachem.com.
Company details
CIN history
Samrat Pharmachem has one previous CIN (Corporate Identification Number): U24230GJ1992PLC017820. The current CIN is L24230GJ1992PLC017820, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24230GJ1992PLC017820 | Current |
| U24230GJ1992PLC017820 | Previous |
Contact details
Samrat Pharmachem Limited's registered office is in Ankleshwar, Gujarat. Its website is samratpharmachem.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressPlot No. A2 – 3444 – 3445, GIDC Phase 4, Ankleshwar, Gujarat, India – 393002
- IndustryChemicals and Materials, Specialty Chemicals
To see the full contact details of Samrat Pharmachem Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Samrat Pharmachem operates one associated brand: Samrat Pharmachem. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Chemicals are manufactured for pharma, food, and fertilizer industries. | samratpharmachem.com |
Business activity
The main business activity of Samrat Pharmachem is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Samrat Pharmachem Limited, buy the company report.
Financials of Samrat Pharmachem Limited
FY 2025-26 filings availableSamrat Pharmachem Limited reported revenue of ₹289.72 Cr (up 1.4% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 290 | 286 | 282 | 311 | 222 | 179 | 137 |
| Revenue growth | +1.4% | +1.5% | -9.4% | +40.1% | +23.9% | +30.2% | - |
| EBITDA | (2.15) | 10.24 | 2.46 | 23.93 | 24.25 | 8.65 | 6.63 |
| EBITDA margin | -0.7% | +3.6% | +0.9% | +7.7% | +10.9% | +4.8% | +4.8% |
| Profit before tax | (3.00) | 9.89 | 2.50 | 22.54 | 23.62 | 7.34 | 5.79 |
| Net profit | (3.65) | 6.72 | 1.25 | 16.64 | 17.22 | 5.34 | 4.25 |
| Net profit margin | -1.3% | +2.4% | +0.4% | +5.4% | +7.8% | +3.0% | +3.1% |
| EPS (₹) | (10.72) | 23.02 | 7.00 | 53.83 | 55.62 | 17.26 | 13.71 |
| Balance sheet | |||||||
| Total assets | 78.89 | 81.72 | 73.45 | 81.80 | 54.34 | 38.43 | 33.71 |
| Net worth | 68.18 | 71.80 | 65.00 | 63.14 | 46.82 | 29.64 | 24.30 |
| Total debt | 10.71 | 9.91 | 8.45 | 18.66 | 7.52 | 8.79 | 9.41 |
| Cash & bank | 6.00 | 0.16 | 9.73 | 11.89 | 14.71 | 2.51 | 1.17 |
| Net working capital | 58.30 | 63.33 | 54.61 | 64.49 | 41.45 | 28.80 | 25.18 |
| Cash flow | |||||||
| Cash from operations | 8.88 | (10.09) | 9.41 | (9.44) | 17.47 | 4.80 | (1.33) |
| Cash from investing | (2.57) | 0.00 | (0.41) | (3.00) | (1.06) | (2.92) | (1.92) |
| Cash from financing | (0.47) | 0.48 | (11.20) | 9.60 | (1.95) | (1.89) | 2.00 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 79.76 | 71.77 | 63.43 | 78.87 | 75.65 | 71.20 | 63.66 | 70.17 |
| Revenue growth (YoY) | +5.4% | +0.8% | -0.4% | +12.4% | -6.4% | - | - | - |
| Other income | 0.99 | (0.31) | 0.40 | 0.05 | 0.69 | (0.11) | 0.00 | 0.49 |
| Total expenses | 78.86 | 73.02 | 64.08 | 79.23 | 75.53 | 71.08 | 59.49 | 66.81 |
| EBITDA | 0.90 | (1.25) | (0.65) | (0.36) | 0.12 | 0.12 | 4.17 | 3.36 |
| EBITDA margin | +1.1% | -1.7% | -1.0% | -0.5% | +0.2% | +0.2% | +6.6% | +4.8% |
| Depreciation | 0.19 | 0.19 | 0.19 | 0.18 | 0.17 | 0.16 | 0.17 | 0.17 |
| Interest | 0.11 | 0.14 | 0.13 | 0.26 | 0.44 | 0.22 | 0.10 | 0.17 |
| Profit before tax | 1.59 | (1.89) | (0.57) | (0.75) | 0.20 | (0.37) | 3.90 | 3.51 |
| Tax | 0.71 | 0.16 | (0.11) | (0.16) | 0.44 | 0.04 | 1.13 | 0.86 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 79.76 | 71.77 | 63.43 | 78.87 | 75.65 | 71.20 | 63.66 | 70.17 |
| Revenue growth (YoY) | +5.4% | +0.8% | -0.4% | +12.4% | -6.4% | - | - | - |
| Other income | 0.99 | (0.31) | 0.40 | 0.05 | 0.69 | (0.11) | 0.00 | 0.49 |
| Total expenses | 78.86 | 73.02 | 64.08 | 79.23 | 75.53 | 71.08 | 59.49 | 66.81 |
| EBITDA | 0.90 | (1.25) | (0.65) | (0.36) | 0.12 | 0.12 | 4.17 | 3.36 |
| EBITDA margin | +1.1% | -1.7% | -1.0% | -0.5% | +0.2% | +0.2% | +6.6% | +4.8% |
| Depreciation | 0.19 | 0.19 | 0.19 | 0.18 | 0.17 | 0.16 | 0.17 | 0.17 |
| Interest | 0.11 | 0.14 | 0.13 | 0.26 | 0.44 | 0.22 | 0.10 | 0.17 |
| Profit before tax | 1.59 | (1.89) | (0.57) | (0.75) | 0.20 | (0.37) | 3.90 | 3.51 |
| Tax | 0.71 | 0.16 | (0.11) | (0.16) | 0.44 | 0.04 | 1.13 | 0.86 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 290 | 286 | 282 | 311 | 222 | 179 | 137 |
| Revenue growth | +1.4% | +1.5% | -9.4% | +40.1% | +23.9% | +30.2% | - |
| Other income | 0.83 | 0.97 | 1.38 | 0.48 | 0.63 | 0.46 | 0.57 |
| Total expenses | 292 | 276 | 279 | 287 | 198 | 170 | 131 |
| Employee cost | 1.17 | 1.11 | 1.11 | 1.07 | 0.96 | 1.05 | 1.00 |
| EBITDA | (2.15) | 10.24 | 2.46 | 23.93 | 24.25 | 8.65 | 6.63 |
| EBITDA margin | -0.7% | +3.6% | +0.9% | +7.7% | +10.9% | +4.8% | +4.8% |
| Depreciation | 0.72 | 0.65 | 0.65 | 0.64 | 0.59 | 0.49 | 0.43 |
| Interest | 0.96 | 0.67 | 0.69 | 1.23 | 0.67 | 1.28 | 0.98 |
| Profit before tax | (3.00) | 9.89 | 2.50 | 22.54 | 23.62 | 7.34 | 5.79 |
| Tax | 0.33 | 2.77 | 0.36 | 5.90 | 6.42 | 2.01 | 1.55 |
| Net profit | (3.65) | 6.72 | 1.25 | 16.64 | 17.22 | 5.34 | 4.25 |
| Net profit margin | -1.3% | +2.4% | +0.4% | +5.4% | +7.8% | +3.0% | +3.1% |
| EPS (₹) | (10.72) | 23.02 | 7.00 | 53.83 | 55.62 | 17.26 | 13.71 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 3.09 | 3.09 | 3.09 | 3.09 | 3.09 | 3.09 | 3.09 |
| Reserves & surplus | 65.09 | 68.71 | 61.91 | 60.05 | 43.73 | 26.55 | 21.21 |
| Shareholders' funds (net worth) | 68.18 | 71.80 | 65.00 | 63.14 | 46.82 | 29.64 | 24.30 |
| Secured loans | 10.71 | 9.91 | 8.45 | 18.66 | 7.52 | 8.79 | 9.41 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total debt | 10.71 | 9.91 | 8.45 | 18.66 | 7.52 | 8.79 | 9.41 |
| Total liabilities | 78.89 | 81.72 | 73.45 | 81.80 | 54.34 | 38.43 | 33.71 |
| Assets | |||||||
| Gross block | 18.80 | 16.85 | 16.62 | 16.25 | 14.89 | 14.00 | 11.44 |
| Net block | 11.72 | 10.48 | 10.73 | 10.70 | 9.98 | 9.40 | 7.19 |
| Capital work in progress | 1.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.08 |
| Investments | 3.87 | 3.80 | 2.93 | 1.88 | 0.01 | 0.00 | 0.00 |
| Inventories | 43.62 | 38.01 | 20.68 | 32.53 | 12.42 | 11.40 | 18.77 |
| Sundry debtors | 51.05 | 56.54 | 69.28 | 51.67 | 43.57 | 33.01 | 27.81 |
| Cash & bank balances | 6.00 | 0.16 | 9.73 | 11.89 | 14.71 | 2.51 | 1.17 |
| Loans & advances | 2.75 | 8.29 | 2.87 | 2.94 | 0.56 | 0.41 | 1.93 |
| Total current assets | 103 | 103 | 103 | 99.03 | 71.26 | 47.33 | 49.68 |
| Total current liabilities | 45.12 | 39.67 | 47.95 | 34.54 | 29.81 | 18.53 | 24.50 |
| Net working capital | 58.30 | 63.33 | 54.61 | 64.49 | 41.45 | 28.80 | 25.18 |
| Total assets | 78.89 | 81.72 | 73.45 | 81.80 | 54.34 | 38.43 | 33.71 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.05 | 9.67 | 11.86 | 14.71 | 0.24 | 0.26 | 1.50 |
| Net cash from operating activities | 8.88 | (10.09) | 9.41 | (9.44) | 17.47 | 4.80 | (1.33) |
| Net cash from investing activities | (2.57) | 0.00 | (0.41) | (3.00) | (1.06) | (2.92) | (1.92) |
| Net cash from financing activities | (0.47) | 0.48 | (11.20) | 9.60 | (1.95) | (1.89) | 2.00 |
| Net change in cash | 5.83 | (9.62) | (2.19) | (2.84) | 14.46 | (0.02) | (1.25) |
| Closing cash | 6.00 | 0.16 | 9.73 | 11.89 | 14.71 | 2.51 | 1.17 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +1.4% | +1.5% | -9.4% | +40.1% | +23.9% | +30.2% | - |
| EBITDA growth | -121.0% | +316.3% | -89.7% | -1.3% | +180.4% | +30.5% | - |
| PBT growth | - | +295.6% | -88.9% | -4.6% | +221.8% | +26.8% | +166.8% |
| Net income growth | -154.3% | +437.6% | -92.5% | -3.4% | +222.5% | +25.7% | - |
| Revenue CAGR (3Y) | -2.3% | +8.8% | +16.3% | +31.2% | +25.9% | +24.4% | +23.6% |
| EBITDA CAGR (3Y) | - | -25.0% | -34.2% | +53.4% | +96.6% | +13.2% | +21.6% |
| Profitability & leverage | |||||||
| Net income margin | -1.2% | +2.5% | +0.8% | +5.4% | +7.8% | +3.0% | +3.1% |
| Return on capital employed | -2.5% | +13.6% | +2.8% | +34.9% | +52.3% | +23.9% | +22.4% |
| Return on net worth | -4.7% | +10.4% | +2.0% | +30.3% | +44.9% | +19.8% | +19.1% |
| Debt / equity | 0.15 | 0.13 | 0.21 | 0.24 | 0.21 | 0.34 | 0.36 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Interest cover | -33.45 | 6.99 | 38.12 | 5.28 | 2.83 | 15.69 | 15.81 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 16.25 | 17.08 | 17.13 | 19.95 | 15.35 | 16.07 | 14.05 |
| Inventory turnover | 7.10 | 9.74 | 10.58 | 13.82 | 18.62 | 13.55 | 11.77 |
| Debtors turnover | 5.39 | 4.54 | 4.66 | 6.52 | 5.79 | 6.72 | 6.43 |
| EPS (₹) | (10.72) | 23.02 | 7.00 | 53.83 | 55.62 | 17.26 | 13.71 |
| Dividend per share (₹) | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 |
| Book value per share (₹) | 220.67 | 232.39 | 210.37 | 204.37 | 151.54 | 95.92 | 78.66 |
To see the full year-wise statements and ratios of Samrat Pharmachem Limited, buy the company report.
Board of directors of Samrat Pharmachem Limited
Samrat Pharmachem has 7 current directors and 5 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Megh Rajesh Mehta | Whole-Time Director | 01 Oct 2015 | 11 Years 1 Months | Current |
| Rajesh Lalit Mehta | Whole-Time Director | 01 Apr 2008 | 18 Years 7 Months | Current |
| Lalit Damodar Mehta | Managing Director | 16 Jun 1992 | 34 Years 4 Months | Current |
| Piyush Gangji Dharod | Director | 16 Jul 2025 | 1 Years 3 Months | Current |
| Manishkumar Indukumar Pipalia | Director | 23 Jul 2024 | 2 Years 3 Months | Current |
| Sachin Samir Kothary | Director | 23 Jul 2024 | 2 Years 3 Months | Current |
Peer comparison
Samrat Pharmachem Limited is compared with the 4 companies closest to it by revenue in the Chemicals industry (Specialty Chemicals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Toyotsu Rare Earths India Private Limited | ₹307.7 Cr (FY 2025) | -29.0% | Anakapalle, Andhra Pradesh, India | |||
| Cetex Petrochemicals Limited | ₹303.99 Cr (FY 2025) | 25.0% | Tamil Nadu, India | |||
| Samrat Pharmachem Limitedthis company | ₹289.72 Cr (FY 2026) | -₹3.65 Cr | -1.3% | 1.4% | 26 | Ankleshwar, Gujarat, India |
| Kukdo Chemical India Private Limited | ₹287.98 Cr (FY 2025) | 83.0% | Vagra, Gujarat, India | |||
| Techno Waxchem Private Limited | ₹283.71 Cr (FY 2025) | 25.0% | Kolkata, West Bengal, India |
To see the full peer comparison of Samrat Pharmachem Limited, buy the company report.
Auditor
Samrat Pharmachem Limited is audited by Shah & Savla LLP for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Shah & Savla LLP | FY 2024 | 109364W/W100143 |
Shareholding
Shareholding for the quarter ended Mar 2026: promoters hold 49.10%, foreign institutional investors hold 3.20%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 47.70%.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | |
|---|---|---|---|---|
| Promoters | 49.10% | 49.10% | 49.10% | 49.10% |
| Public | 50.90% | 50.90% | 50.90% | 50.90% |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 05 Dec 2011 | 10322529 | Others | ₹4 Cr | Open | |
| 21 Oct 2011 | 10313445 | Icici Bank Limited | ₹2 Cr | Open | |
| 22 Dec 2007 | 10101754 | Others | ₹46 Cr | Open | |
| 02 Nov 2005 | 80001467 | Others | ₹17 Cr | Open | |
| 19 Oct 2011 | 10312791 | Hdfc Bank Limited | ₹3.2 Cr | Satisfied |
To see the full charge records of Samrat Pharmachem Limited, buy the company report.
Total charge records: 9 View all charges
Deals & funding
Samrat Pharmachem Limited has 31 deals on record (31 market trades); the latest was in September 2024.
Deals on record (5 of 31)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Sep 2024 | Market trade | ₹68.2 Lakh | Seller: Golechha Global Finance Limited |
| Aug 2023 | Market trade | ₹1.29 Cr | Buyer: Setu Securities Private Limited Seller: Alert Consultants & Credit Pvt Ltd , Setu Securities Private Limited |
| Jul 2023 | Market trade | ₹95.9 Lakh | Seller: Golechha Global Finance Limited |
| Jan 2022 | Market trade | ₹5.5 Cr | Buyer: Advani Pvt Ltd Seller: an individual |
| Mar 2012 | Market trade | ₹10.8 Lakh | Buyer: Lake City Traders Private Limited |
To see the full deal history of Samrat Pharmachem Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Samrat Pharmachem Limited has 20 court cases on record: 7 filed by Samrat Pharmachem, 13 filed against it. 1 case is pending and 19 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 19 | 13 | 1 |
| High courts | 1 | 0 | 0 |
Cases on record (5 of 20)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Mumbai CMM Courts, Maharashtra | Court case (Summons Private cases SS) | Filed by the company against M/S. Wellcure Pharma India Pvt. Ltd | Pending |
| District court, Mumbai CMM Courts, Maharashtra | Court case (Summons warrent Cases SW) | Filed by the company against Om Salt Refinery Pvt Ltd and 4 Oth and 4 others | Disposed |
| District court, Ahmedabad, Gujarat | Criminal complaint | Filed by the company against Romano Drugs Pvt Ltd and 2 others | Disposed |
| District court, Mumbai CMM Courts, Maharashtra | Court case (Summons Private cases SS) | Filed by the company against Romano Drugs Pvt Ltd | Disposed |
| District court, Bharuch, Gujarat | Court case (REFER T LC) | Filed against the company by an individual | Disposed |
To see the full case history of Samrat Pharmachem Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Samrat Pharmachem Limited was last rated by Crisil on 31 Oct 2020.
| Rating agency | Rated on | Rating |
|---|---|---|
| Crisil | 31 Oct 2020 |
To see the full credit ratings and regulatory alerts of Samrat Pharmachem Limited, buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Samrat Pharmachem Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Samrat Pharmachem Limited has a workforce of 26 employees on its EPFO records as of Aug 19, 2025, across 1 active EPFO establishment.
GST
Samrat Pharmachem has 3 GST registrations: 1 active and 2 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AAECS0806M2ZE | Gujarat | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Samrat Pharmachem Limited, buy the company report.
Recent activity
Samrat Pharmachem Limited has 17 board changes on record since 1992: 12 appointments and 5 cessations. The latest: Piyush Gangji Dharod was appointed as Director on 16 Jul 2025.
28 earlier events are in the company report.
News
Frequently asked questions
Samrat Pharmachem is an active public limited company based in Ankleshwar, Gujarat, India. The company works in specialty chemicals, within the chemicals and materials industry. It was incorporated on 16 June 1992 (34+ years old) and is registered under CIN L24230GJ1992PLC017820. Listed on BSE: 530125.
Samrat Pharmachem reported revenue of ₹289.72 Cr for FY 2025-26 (up 1.4% YoY) based on standalone financials.
Samrat Pharmachem has 7 current directors:
- Lalit Damodar Mehta - Managing Director
- Megh Rajesh Mehta - Whole-Time Director
- Rajesh Lalit Mehta - Whole-Time Director
- Piyush Gangji Dharod - Director
- Manishkumar Indukumar Pipalia - Director
- Sachin Samir Kothary - Director
- Megha Sanjay Jain - Additional Director
The latest financial statements of Samrat Pharmachem on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 25 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Samrat Pharmachem is 24AAECS0806M2ZE, registered in Gujarat. The company has 3 GST registrations in all, of which 1 is active and 2 are cancelled or inactive.
The CIN (Corporate Identification Number) of Samrat Pharmachem is L24230GJ1992PLC017820. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Samrat Pharmachem is a listed company as per MCA records. Its shares are listed on BSE (code: 530125).
Samrat Pharmachem has 20 court cases on record: 7 filed by the company and 13 filed against it. 1 is pending. Most are in the district courts.
Samrat Pharmachem was incorporated on 16 June 1992, making it 34+ years old. It is registered with the Registrar of Companies, Ahmedabad.
Samrat Pharmachem has 31 deals on record (31 market trades); the latest was in September 2024.
The peers of Samrat Pharmachem by revenue are Toyotsu Rare Earths India Private Limited, Cetex Petrochemicals Limited, Kukdo Chemical India Private Limited, Techno Waxchem Private Limited, all in the Chemicals industry (Specialty Chemicals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
